LOYOLA UNIVERSITY CHICAGO Patent applications |
Patent application number | Title | Published |
20140341935 | MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE - A vaccine and method of treatment suitable for treating autoimmune diseases, such as Vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 DNA sequence encoding the peptide. | 11-20-2014 |
20140243579 | DUAL-ENERGY IMAGE SUPPRESSION METHOD - An imaging process capable of selectively enhancing visualization of soft tissues, for example, a tumor. The imaging process includes producing a hard tissue-enhanced image of a body containing both soft and hard tissues, wherein the hard tissue-enhanced image contains images of the hard tissues that are enhanced relative to the soft tissues. A radiographic image of the body and the soft and hard tissues thereof are then obtained, after which a weighted subtraction algorithm is performed between the radiographic image and the hard tissue-enhanced image to produce a soft tissue-enhanced image in which imaging of the soft tissues is enhanced relative to the hard tissues. The hard tissue-enhanced image may be produced by obtaining first and second initial radiographic images of the body including the soft and hard tissues, and then performing a weighted subtraction algorithm on the first and second initial radiographic images to produce the hard tissue-enhanced image. | 08-28-2014 |
20140155368 | COMBINATION PHARMACEUTICALS AND METHODS THEREOF USING PROTEINACIOUS CHANNELS AS TREATMENTS FOR MEDICAL CONDITIONS - Methods and combination pharmaceuticals for treating bronchospastic medical conditions by utilizing the electrophysiology of proteinacious channels in lipid membranes of mammalian cells. The combination pharmaceuticals include at least one β-adrenergic receptor agonist, and at least one composition adapted to effect the electrophysiology of Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell. The pharmaceutical may be administered to a living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell. | 06-05-2014 |
20130231262 | ENGINEERED PROTEIN: "2-COLOR SERCA", AN ION-MOTIVE ATPase FUSED TO CERULEAN AND YELLOW FLUORESCENT PROTEIN - A method and engineered proteins for use therewith suitable for studying SERCA that are capable of being used in vivo and do not require protein purification or chemical labeling of SERCA, or reconstitution into artificial membranes. The engineered protein for calcium handling within human cells includes a two-color SERCA construct having three component proteins fused together. The three component proteins include a blue fluorescent protein (cerulean), SERCA2a and a yellow fluorescent protein (YFP), or a red fluorescent protein (tagRFP acceptor), SERCA and a green fluorescent protein (GFP). The method of determining SERCA activity for optimization of cardiac function includes resolving structure changes of the two-color SERCA construct. The two-color SERCA constructs are catalytically active and able to pump calcium following the step of resolving structure changes. | 09-05-2013 |
20120282618 | METHODS AND ASSAYS FOR RISK PREDICTION, DIAGNOSIS, AND ANALYSIS OF MYOCARDIAL INFARCTION, HEART FAILURE AND REDUCED CARDIAC FUNCTION - Methods and kits adapted for risk prediction, diagnosis, and analysis of myocardial infarction (MI), myocardial failure, and reduced cardiac function such as heart failure. The methods include collecting a sample of human body fluid or tissue from a subject and then identifying the presence of cardiac myosin binding protein-C 25-nucleotide deletion and/or detecting the presence of cardiac myosin binding protein-C, its peptides, its phosphorylation status, and/or its autoantibodies in the human body fluid or tissue. | 11-08-2012 |
20120059044 | METHODS OF UTILIZING THE ARRESTIN-2/STAM-1 COMPLEX AS A THERAPEUTIC TARGET - Methods of utilizing the arrestin-2/sTAM-1 complex as a therapeutic target. The methods include treating cells of a living organism to mediate an interaction between arrestin-2 and STAM-1 adapter protein molecules, wherein the interaction is characterized by the arrestin-2 adapter protein molecule directly binding to the STAM-2 adapter protein molecule. Pharmacological agents can be identified for therapeutic uses by determining whether the pharmacological agent disrupts the interaction between the arrestin-2 and STAM-1 adapter protein molecules. | 03-08-2012 |
20110081321 | OMENTUM AS A SOURCE OF STROMAL/STEM CELLS AND MEDICAL TREATMENTS USING STROMAL/STEM CELLS - Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue. The invention also encompasses a medical procedure comprising the transfer of omental stem cells to a patient, and a procedure comprising in vitro activation of omental stem cells by T cells to enhance immunomodulatory functions of the omental stem cells. | 04-07-2011 |
20100273851 | METHODS OF USING PROTEINACIOUS CHANNELS TO IDENTIFY PHARMACEUTICAL TREATMENTS AND RISKS, AND TREATMENTS RESULTING THEREFROM - Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one proteinacious channel of the lipid membrane, wherein the proteinacious channel is a Kv7 potassium channel and/or a L-type calcium channel of an airway smooth muscle cell (ASMC). The method can be used to identify pharmaceuticals that may be used to treat asthmatic and other bronchospastic conditions that can lead to airway obstruction, or to perform drug screening to assess potential risk of pharmaceuticals. | 10-28-2010 |
20100167399 | METHOD OF GENERATING REGULATORY T CELLS USING CORD BLOOD AND ADULT BLOOD CD14+ MONOCYTE CELLS - A method of inducing stable and functional Tregs from human umbilical cord blood and adult blood without requiring the expansion of pre-existing Tregs. The method utilizes CD14+ monocyte cells present in or isolated from cord blood or adult blood to induce functional Tregs from T cells, and particularly T cells that express CD4+, which may also be obtained from cord blood or adult blood. The developed Tregs are long-lasting and maintain their suppressive functions. | 07-01-2010 |
20100113553 | METHODS OF USING PROTEINACIOUS CHANNELS TO IDENTIFY PHARMACEUTICAL TREATMENTS AND RISKS, AND TREATMENTS RESULTING THEREFROM - Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one vascular proteinacious channel of the lipid membrane, wherein the vascular proteinacious channel is a vascular Kv7 potassium channel and/or a vascular L-type calcium channel. The method can be used to identify pharmaceuticals that may be used to treat hypertension and/or vasospastic conditions, or to perform drug screening to assess potential cardiovascular risk of pharmaceuticals. | 05-06-2010 |